Medicare Enrolled
Dr. Siva Gummadi, M.D.
Cardiovascular Disease · Ocala, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gummadi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gummadi? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gummadi
Dr. Siva Gummadi is a cardiovascular disease in Ocala, FL, with 19 years in practice. Based on federal Medicare data, Dr. Gummadi performed 15,716 Medicare services across 6,591 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gummadi received a total of $17,802 from 45 pharmaceutical and/or device companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gummadi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 3% volume in FL$ $17,802 industry payments
Medicare Practice Summary
Medicare Utilization ↗15,716
Medicare services
Top 3% in FL for cardiovascular disease
6,591
Unique beneficiaries
$110
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~827 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 4,750 | $0 | $0 |
| Office visit, established patient (30-39 min) | 2,441 | $91 | $233 |
| Regadenoson injection (Lexiscan) for heart stress test | 1,272 | $44 | $108 |
| Echocardiogram, transthoracic | 995 | $75 | $214 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 568 | $313 | $800 |
| Ultrasound of both sides of head and neck blood flow | 497 | $42 | $119 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 352 | $27 | $71 |
| Ultrasound of leg arteries or artery grafts | 335 | $71 | $199 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 325 | $53 | $142 |
| Electrocardiogram (EKG), 12-lead | 321 | $11 | $36 |
| Remote pacemaker/defibrillator monitoring, 90 days | 309 | $15 | $49 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 284 | $2,057 | $4,763 |
| Nuclear medicine study of heart muscle blood flow by pet | 281 | $139 | $342 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 258 | $9 | $22 |
| Remote pacemaker monitoring, 90 days | 206 | $21 | $61 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 184 | $20 | $53 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 171 | $20 | $54 |
| New patient office visit (45-59 min) | 160 | $121 | $333 |
| Office visit, established patient (20-29 min) | 160 | $54 | $156 |
| Injection, midazolam hydrochloride, per 1 mg | 148 | $0 | $1 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 130 | $45 | $166 |
| Prothrombin time test (blood clotting) | 129 | $4 | $11 |
| Programming of dual lead pacemaker system | 129 | $54 | $139 |
| Anticoagulant management of patient taking warfarin | 126 | $8 | $24 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 118 | $32 | $91 |
| Hospital follow-up visit, moderate complexity | 112 | $64 | $148 |
| Initial hospital admission, moderate complexity | 110 | $104 | $279 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 107 | $25 | $101 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 104 | $167 | $215 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 86 | $39 | $101 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $250 | $705 |
| Review by radiologist of abdominal aorta image | 46 | $97 | $279 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 44 | $141 | $384 |
| Review by radiologist of arm or leg artery image | 34 | $119 | $330 |
| Ultrasound of heart, follow-up | 33 | $58 | $175 |
| Removal of plaque in arteries of leg | 32 | $5,964 | $17,594 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 31 | $19 | $52 |
| Hospital follow-up visit, low complexity | 29 | $40 | $80 |
| Programming of dual lead implantable defibrillator system | 28 | $73 | $180 |
| Programming of single lead pacemaker system | 25 | $48 | $119 |
| Programming of multiple lead implantable defibrillator system | 24 | $72 | $194 |
| Ultrasound of one leg arteries or artery grafts | 23 | $81 | $238 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 20 | $20 | $53 |
| Balloon dilation of artery of leg, initial vessel | 17 | $1,960 | $9,036 |
| Removal of plaque in artery of leg, initial vessel | 16 | $6,607 | $18,314 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial second order branch | 14 | $419 | $1,974 |
| Review by radiologist of both arms or legs arteries image | 14 | $128 | $383 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 14 | $20 | $76 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $11 | $30 |
| Insertion of tube into abdominal, pelvic, or leg artery, initial third order branch | 12 | $1,039 | $3,061 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 12 | $626 | $1,401 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.4% high complexity
51.5% medium
36.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,802
Total received (2018-2024)
Avg $2,543/year across 7 years
Top 15% in FL for cardiovascular disease
45
Companies
541
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,564 (76.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,238 (23.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,714
2023$2,379
2022$2,827
2021$2,738
2020$711
2019$1,070
2018$5,362
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$4,840
Janssen Pharmaceuticals, Inc
$1,783
AngioDynamics, Inc.
$1,648
Cook Medical LLC
$1,116
PFIZER INC.
$963
Boston Scientific Corporation
$754
Abbott Laboratories
$736
Amgen Inc.
$724
Medtronic Vascular, Inc.
$432
Boehringer Ingelheim Pharmaceuticals, Inc.
$332
E.R. Squibb & Sons, L.L.C.
$330
Medtronic, Inc.
$315
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$305
Merck Sharp & Dohme LLC
$297
Impulse Dynamics (USA) Inc.
$257
BOSTON SCIENTIFIC CORPORATION
$255
SANOFI-AVENTIS U.S. LLC
$228
AstraZeneca Pharmaceuticals LP
$227
Veryan Medical Incorporated
$203
BIOTRONIK INC.
$192
Astellas Pharma US Inc
$185
Ironwood Pharmaceuticals, Inc
$157
CVRx, Inc.
$143
Braemar Manufacturing, LLC
$138
Silk Road Medical, Inc.
$133
Stryker Corporation
$125
Penumbra, Inc.
$120
Philips Electronics North America Corporation
$100
GE HealthCare
$92
Merck Sharp & Dohme Corporation
$90
ATRICURE, INC.
$83
Kestra Medical Technology Services, Inc.
$83
Regeneron Healthcare Solutions, Inc.
$68
Amarin Pharma Inc.
$56
Cardiovascular Systems Inc.
$43
Esperion Therapeutics, Inc.
$39
Bardy Diagnostics, Inc.
$38
Novo Nordisk Inc
$32
Aziyo Biologics, Inc.
$30
Edwards Lifesciences Corporation
$24
Philips North America LLC
$22
Lexicon Pharmaceuticals, Inc.
$20
Lundbeck LLC
$17
Smith & Nephew, Inc.
$16
Elutia, Inc.
$13
Top 3 companies account for 46.5% of total payments
Associated products mentioned in payments ›
(5044) MCOT · (5091) Amb Mon & Diag Und · (CK4) MCOT · ADVANCE · ANDEXXA · ATRICLIP LAA EXCLUSION SYSTEM · AURYON LASER SYSTEM 100-120 VAC · AVEIR · Acticor · Advisa · Armada 35 percutaneous catheter · Assure WCD · Auryon Laser System 100-120 Vac · Azure · BRILINTA · Barostim Neo System · BioMimics 3D Vascular Stent System · CAMZYOS · COOK MEDICAL ANGIOPLASTY · COOK MEDICAL LEAD MANAGEMENT · COOK MEDICAL ZILVER PTX · Cardiac Monitoring Suite · Carnation Ambulatory Monitor · Claria MRI · ClosureFast · Confirm Rx · Cook Medical Stents · Cook Medical Zilver PTX · Corlanor · DYNAGEN MINI ICD VR · Diamondback Peripheral · ECM Patch · ELIQUIS · ENROUTE Transcarotid Neuroprotection System · ENTRESTO · EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · GENERAL THERAPIES · GENERAL - THERAPIES · HawkOne · HeartMate 3 Left Ventricular Dev · IN.PACT Admiral · Inpefa · JARDIANCE · JOT DX · LEQVIO · LEXISCAN · LINQ II · LINZESS · LOKELMA · LUX-DX · LUX-Dx Insertable Cardiac Monitor · LifeVest · MAKO · MITRACLIP · MULTAQ · Mitra Clip system · MitraClip System · NEXLETOL · NORTHERA · Optimizer · Optimizer Smart System · Ozempic · PK Papyrus · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Penumbra System · Peripheral Orbital Atherectomy System · Pouch · RESONATE EL ICD VR · Repatha · Reveal LINQ · Santyl · TURBOHAWK · VERQUVO · VIGILANT X4 CRT-D · VYNDAQEL · Varithena Administration Pack · Vascepa · VenaCure 1470 Pro · WALLSTENT · WATCHMAN FLX · XARELTO · XXL · ZENITH ALPHA · ZILVER 635 · ZILVER PTX · Zero Gravity · Zilver PTX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (76%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $113 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
53
Per 100K population
13.7
County median income
$58,535
Nearest hospital
MARION COMMUNTIY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Gummadi is a clinical cardiology specialist, with above-average Medicare volume (top 3% in FL), and high industry engagement (low-engagement, top 15%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Gummadi experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Gummadi performed 4,750 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gummadi receive payments from pharmaceutical companies?
Yes. Dr. Gummadi received a total of $17,802 from 45 companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gummadi's costs compare to other cardiovascular diseases in Ocala?
Dr. Gummadi's average Medicare payment per service is $110. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gummadi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Ocala
Browse cardiovascular diseases in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in FL
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in FL
Which FL cardiovascular diseases receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
AngioDynamics, Inc. Payments to Doctors
See all physicians who received payments from AngioDynamics, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology